CD8A and melanoma: This strategy has been used in a phase I clinical trial in renal cell carcinoma, newly diagnosed and recurrent pediatric brain tumors, prostate cancer, and melanoma.[73] The use of tumor RNA‐pulsed DCs was reliable in expanding CD4+ and CD8+ tumor‐reactive T lymphocytes, for curative adoptive cellular therapy in a highly‐invasive, chemotherapy‐ and radiation‐resistant malignant glioma model.[74] Transfection of DCs with whole cell RNA is more effective than that with DNA vector constructs.